Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 2, randomised, double-blind trial of belimumab in Allograft Rejection (AR), sponsored by GSK. Started Sep 2013; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults aged 18-75 undergoing kidney transplantation, planned to receive standard immunosuppression (basiliximab, MMF, tacrolimus, prednisolone).
04
Results
Not all primary endpoints met
05
Registry description
Kidney transplantation is the best treatment for many patients with kidney failure. Sometimes a transplanted kidney is rejected by the patient's immune system. Many types of immune system cells, including B cells, are active in rejection. B cells produce antibodies against anything the body sees as non-self, like germs or a transplanted kidney. Most medicines that help prevent transplant rejection affect cells other than B cells. Belimumab is a medication used to treat a disease called lupus. Belimumab slows development of antibody-producing B cells. This study will test whether belimumab…
Beyond the preview
Go deeper on NCT01536379.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01536379.